You are currently logged into
Cancer Health Directory - My Account or Log Out
Cancer Health Cancer Health
  • Home
  • News
    • News
    • Newsfeed
    • Treatment News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Cancer Health TV
    • By Author
    • RSS Links
  • Cancer Basics
    • Cancer 101
    • Newly Diagnosed
    • Living with Cancer
    • Cancer Treatment
    • Cancer Medications
    • Breast Cancer
    • Colon Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • More Types of Cancer
    • Resources
  • Hot Topics
    • Coronavirus (COVID-19)
    • Health Equity
    • Cancer Treatment
    • Car-T Therapy
    • Caregivers
    • Chemotherapy
    • Immunotherapy
    • Marijuana
    • Mental Health
    • Quality of Life
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Cancer Health Focus
    • Bulk Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Cancer Health Stories
    • Cancer Health Forums
    • Ask Cancer Health
    • Polls
    • Surveys
    • Quizzes
    • Calendar
    • Volunteer Jobs
    • Bookstore
    • Amazon Store
  • About Us
    • About Us
    • Masthead
    • Advertise
    • Awards
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Padcev

Tweet
  • Share

Padcev Improves Overall Survival in People With Bladder Cancer

The 30% improvement in survival has brought a Phase III trial to an early halt.

Special Delivery

Last year, the FDA approved three new antibody-drug conjugates for treating cancer.

Padcev Combo Continues to Show Promise for Advanced Bladder Cancer

Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.

Top 10 Cancer Treatment Highlights of 2019

Padcev

FDA Approves Padcev for Advanced Bladder Cancer

Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.

New Combo Shows Promise as Treatment for Advanced Bladder Cancer

Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.

New Targeted Antibody Treatment for Bladder Cancer Shows Promise

More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.